

Berna C Ã-zdemir

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5927131/publications.pdf>

Version: 2024-02-01

20
papers

2,946
citations

759233

12
h-index

794594

19
g-index

22
all docs

22
docs citations

22
times ranked

6284
citing authors

#	ARTICLE	IF	CITATIONS
1	Prescription Patterns, Recurrence, and Toxicity Rates of Adjuvant Treatment for Stage III/IV Melanomaâ€”A Real World Single-Center Analysis. <i>Biology</i> , 2022, 11, 422.	2.8	4
2	Sex and Gender Differences in Anticancer Treatment Toxicity: A Call for Revisiting Drug Dosing in Oncology. <i>Endocrinology</i> , 2022, 163, .	2.8	21
3	Immune checkpoint inhibitor-related hypogonadism and infertility: a neglected issue in immuno-oncology. , 2021, 9, e002220.		22
4	Acute cardiac manifestations under immune checkpoint inhibitorsâ€”beware of the obvious: a case report. <i>European Heart Journal - Case Reports</i> , 2021, 5, ytab262.	0.6	6
5	Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors. <i>Cancer Treatment Reviews</i> , 2021, 100, 102282.	7.7	25
6	Sustained androgen receptor signaling is a determinant of melanoma cell growth potential and tumorigenesis. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	31
7	Androgen Signaling in the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1270, 169-183.	1.6	1
8	Personalized treatment of immune checkpoint inhibitor-related severe hemophagocytic lymphohistiocytosis (HLH).. <i>Journal of Clinical Oncology</i> , 2020, 38, e15079-e15079.	1.6	0
9	Long-lasting, irreversible and late-onset immune-related adverse events (irAEs) from immune checkpoint inhibitors (ICIs): A real-world data analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, e15095-e15095.	1.6	3
10	Deep Response to Anti-PD-1 Therapy of Metastatic Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumor With <i>CD274/PD-L1</i> Amplification. <i>JCO Precision Oncology</i> , 2019, 3, 1-6.	3.0	10
11	Sex Hormones and Anticancer Immunity. <i>Clinical Cancer Research</i> , 2019, 25, 4603-4610.	7.0	82
12	Human epidermal growth factor receptor 2-positive digestive tumors. <i>Current Opinion in Oncology</i> , 2019, 31, 354-361.	2.4	4
13	The challenges of modeling hormone receptor-positive breast cancer in mice. <i>Endocrine-Related Cancer</i> , 2018, 25, R319-R330.	3.1	33
14	Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature. <i>European Urology Focus</i> , 2018, 4, 442-454.	3.1	10
15	Sex Differences in Efficacy and Toxicity of Systemic Treatments: An Undervalued Issue in the Era of Precision Oncology. <i>Journal of Clinical Oncology</i> , 2018, 36, 2680-2683.	1.6	100
16	Androgen receptor functions as transcriptional repressor of cancer-associated fibroblast activation. <i>Journal of Clinical Investigation</i> , 2018, 128, 5531-5548.	8.2	40
17	Racial Differences in Cancer Susceptibility and Survival: More Than the Color of the Skin?. <i>Trends in Cancer</i> , 2017, 3, 181-197.	7.4	116
18	The Molecular Signature of the Stroma Response in Prostate Cancer-Induced Osteoblastic Bone Metastasis Highlights Expansion of Hematopoietic and Prostate Epithelial Stem Cell Niches. <i>PLoS ONE</i> , 2014, 9, e114530.	2.5	42

#	ARTICLE	IF	CITATIONS
19	Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival. <i>Cancer Cell</i> , 2014, 25, 719-734.	16.8	1,892
20	TGF- β 2-Containing Exosomes from Injured Epithelial Cells Activate Fibroblasts to Initiate Tissue Regenerative Responses and Fibrosis. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 385-392.	6.1	340